An interventional study of Imagery Rescripting in Panic Disorder, sponsored by İmge eylem yılmaz namlı. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-08-18.
Sponsored by İmge eylem yılmaz namlı · Not applicable, Interventional, and Treatment
The current project consists of two studies investigating the phenomenological characteristics, centrality levels, and traumatic symptoms of panic attack memories, while testing the effectiveness of the Imagery Rescripting (ImRs) intervention in the treatment of panic disorder.
The first study investigates whether panic attack memories share similar phenomenological features, centrality levels, and physiological responses with classic traumatic memories and general negative life event memories in a sample of 152 participants.
The second study is a randomized controlled trial (RCT) involving 32 participants diagnosed with panic disorder based on DSM-5 criteria. Participants are randomly assigned to either an Imagery Rescripting (ImRs) intervention group or a control group. The primary objective is to evaluate the clinical effectiveness of a 6-session ImRs protocol in reducing panic disorder symptoms and physiological arousal associated with panic attack memories.
This research project investigates the traumatic properties of panic attack memories and evaluates the therapeutic efficacy of an Imagery Rescripting (ImRs) intervention for individuals diagnosed with Panic Disorder through two interconnected studies. Study 1 utilizes a comparative cross-sectional design with 152 participants to examine the phenomenological characteristics, event centrality, traumatic stress symptom severity, and physiological reactivity of panic attack memories in comparison to classic traumatic memories and negative life event memories. During a structured memory recall and writing task, real-time physiological arousal is recorded via skin conductance and heart rate measurements, followed by the administration of self-report measures including the Autobiographical Memory Characteristics Questionnaire, the Centrality of Event Scale, and the Impact of Event Scale. Building upon these baseline phenomenological findings, Study 2 employs a randomized controlled trial (RCT) design to evaluate the clinical efficacy of Imagery Rescripting in a clinical sample of 32 participants meeting DSM-5 criteria for Panic Disorder. Participants are stratified by gender and randomly assigned to either an Intervention Group (n = 16), receiving a 6-session structured ImRs protocol incorporating psychoeducation, breathing exercises, and healthy adult mode rescripting, or a Control Group (n = 16) serving as a comparison condition. Treatment outcomes across both psychological and physiological domains-assessed via the Autobiographical Memory Characteristics Questionnaire, Centrality of Event Scale, Impact of Event Scale, DSM-5 Panic Disorder Scale, General Self-Efficacy Scale, Panic Self-Efficacy Single-Item Question, and skin conductance/heart rate tracking-are evaluated across three distinct time points: Baseline (Session 1), Post-Intervention (Session 6, following 6 weekly sessions), and a 1-Month Follow-Up (Session 7).
270 studies on the registry are indexed under Panic Disorder; 37 are open to participants now.
This study's enrollment of 32 is below the median of 77 across 215 interventional studies indexed under Panic Disorder.
Browse Panic Disorder studies →This is the only study on the registry with İmge eylem yılmaz namlı as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Being aged between 18 and 65 years. Voluntarily agreeing to participate in the study and providing .
Being fluent in written and spoken Turkish. Having a current diagnosis of Panic Disorder according to criteria, confirmed by a psychiatrist.
Answering "No" to the traumatic event screening question regarding the index panic memory (i.e., the panic memory does not involve exposure to actual or threatened death, serious injury, or physical threat).
Exclusion Criteria:
Being under 18 or over 65 years of age. Inability or unwillingness to provide . Insufficient Turkish literacy. Absence of a current psychiatric diagnosis of Panic Disorder according to criteria.
Having a lifetime diagnosis of Post-Traumatic Stress Disorder (PTSD) according to DSM-5 criteria.
Answering "Yes" to the traumatic event screening question (i.e., presence of an explicit Criterion A traumatic event/physical threat in the index memory).
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this arm receive a structured 6-session Imagery Rescripting (ImRs) protocol targeting traumatic panic attack memories. The intervention incorporates psychoeducation regarding panic symptoms and autobiographical memory, breathing exercises, and imagery rescripting techniques aimed at modifying the traumatic components of panic memories and developing a healthy adult perspective.
Behavioral: Imagery Rescripting
Participants in this arm are assigned to the control group and do not receive the Imagery Rescripting intervention during the active study phase. Assessment data (physiological measurements and psychological scales) are collected at parallel time points corresponding to the baseline, post-intervention, and 1-month follow-up of the intervention group.
The protocol consists of a 6-session Imagery Rescripting (ImRs) intervention followed by a 1-month follow-up assessment. Session 1 involves introduction, study orientation and baseline assessments (physiological recordings during memory writing and psychological scales). Session 2 covers psychoeducation on panic disorder, breathing exercises, and the Safe Place exercise. Session 3 introduces Healthy Adult Imagery to foster adaptive coping mechanisms. Sessions 4 and 5 consist of core ImRs applications targeting traumatic panic attack memories and related early memories, utilizing therapist- or client-led adult interventions to fulfill unmet emotional needs. Session 6 evaluates the intervention outcomes, future concerns and collects post-intervention measurements. Session 7 serves as a 1-month follow-up evaluation with no active intervention.
Change from Baseline in DSM-5 Panic Disorder Symptom Severity at Post-Intervention and 1-Month Follow-Up
The DSM-5 Panic Disorder Scale (American Psychiatric Association, 2013; Turkish validation by Balıkçı et al., 2017) was used to measure the severity of panic disorder symptoms over the past 7 days. The scale is a 10-item, single-factor measure. The internal consistency coefficient (Cronbach's alpha) for the Turkish version was reported as .96. Higher scores reflect greater severity of panic disorder symptoms.
Time frame: Baseline, 6 weeks (post-treatment, following six weekly 50-minute sessions), and 1-month post-treatment follow-up
Change from Baseline in Physiological Reactivity (Heart Rate) During Panic Attack Memory Recall at Post-Intervention and 1-Month Follow-Up
Assessed by recording Heart Rate (beats per minute, BpM) an indicator of autonomic nervous system arousal during the panic attack memory writing/recall task. Data are recorded using NeuLog Heart Rate \& Pulse Logger Sensor (NUL-208) attached to the ring finger of the non-dominant hand. Higher values of heart rate reflect greater autonomic arousal and physiological reactivity during traumatic memory recall.
Time frame: Baseline, 6 weeks (post-treatment, following six weekly 50-minute sessions), and 1-month post-treatment follow-up
Change from Baseline in Physiological Reactivity (Skin Conductance Level) During Panic Attack Memory Recall at Post-Intervention and 1-Month Follow-Up
Assessed by recording Skin Conductance (microSiemens) as indicators of autonomic nervous system arousal during the panic attack memory writing/recall task. Data are recorded using NeuLog NeuLog GSR Logger Sensor (NUL-217) attached to the index finger of the non-dominant hand. Higher values of the skin conductance reflect greater autonomic arousal and physiological reactivity during traumatic memory recall.
Time frame: Baseline, 6 weeks (post-treatment, following six weekly 50-minute sessions), and 1-month post-treatment follow-up
Change from Baseline in Phenomenological Characteristics of Autobiographical Memory at Post-Intervention and 1-Month Follow-Up
To assess the phenomenological properties of autobiographical memories, the 63-item Autobiographical Memory Characteristics Questionnaire (Boyacıoğlu \& Akfırat, 2015) was utilized. The questionnaire comprises 8 subscales: narrative coherence, reliving, vividness, perceptual detail, field perspective, observer perspective, emotional valence, and emotional intensity. Together, these subscales account for 72% of the total scale variance. In the original validation study, the internal consistency coefficients (Cronbach's alpha) for the subscales ranged from .66 to .97.
Time frame: Baseline, 6 weeks (post-treatment, following six weekly 50-minute sessions), and 1-month post-treatment follow-up
Change from Baseline in Event Centrality Score at Post-Intervention and 1-Month Follow-Up
Assessed using the 7-item short form of the Centrality of Event Scale (CES) (Berntsen \& Rubin, 2006; Turkish adaptation by Boyacıoğlu \& Aktaş, 2018) to measure the extent to which the traumatic panic memory is integrated into the participant's identity and life story (Cronbach alpha = .89 for negative memories). Items are rated on a 5-point Likert scale, with total scores ranging from 7 to 35. Higher scores reflect greater event centrality.
Time frame: Baseline, 6 weeks (post-treatment, following six weekly 50-minute sessions), and 1-month post-treatment follow-up
Change from Baseline in Traumatic Stress Symptom Severity at Post-Intervention and 1-Month Follow-Up
Assessed using the 22-item Turkish version of the Impact of Event Scale-Revised (IES-R) (Weiss \& Marmar, 1997; Turkish adaptation by Çorapçıoğlu et al., 2006) to evaluate traumatic stress symptoms associated with panic memories over the past week. The scale consists of 3 subscales: Intrusion, Avoidance, and Hyperarousal. Internal consistency values range from .88 to .94. Total scores range from 0 to 88, with higher scores indicating greater severity of post-traumatic stress symptoms.
Time frame: Baseline, 6 weeks (post-treatment, following six weekly 50-minute sessions), and 1-month post-treatment follow-up
Change from Baseline in General Self-Efficacy Score at Post-Intervention and 1-Month Follow-Up
Assessed using the 17-item Turkish version of the General Self-Efficacy Scale (Sherer et al., 1982; Turkish adaptation by Yıldırım \& Özgür İlhan, 2010) to evaluate individuals' belief in their ability to cope with challenging life events. The scale demonstrates a three-factor structure accounting for 41.47% of the total variance, with an internal consistency coefficient of Cronbach alpha = .80. Higher scores indicate higher levels of perceived general self-efficacy.
Time frame: Baseline, 6 weeks (post-treatment, following six weekly 50-minute sessions), and 1-month post-treatment follow-up
Change from Baseline in Perceived Panic Self-Efficacy Score at Post-Intervention and 1-Month Follow-Up
Assessed using a single-item question rated on a 6-point Likert scale (ranging from 0 = "Not confident at all" to 5 = "Completely confident"), adapted based on the work by Helbig-Lang (2012). The item asks: "How confident do you feel in your ability to cope with a potential panic attack in the future?" Higher scores reflect greater perceived self-efficacy in managing future panic attacks.
Time frame: Baseline, 6 weeks (post-treatment, following six weekly 50-minute sessions), and 1-month post-treatment follow-up
Plan to share: No — Individual participant data will not be shared in order to protect participant confidentiality and privacy, as explicit consent for raw data sharing was not obtained from participants in accordance with the institutional review board (IRB) approval and national data protection regulations. De-identified aggregated data will be made available through peer-reviewed publication results.
No publications or documents are linked to this record.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.